Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases - PubMed (original) (raw)
Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases
Alexandar Tzankov et al. Mod Pathol. 2003 Nov.
Abstract
Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma arise from B-lymphocytes. However, classical markers of the B-cell phenotype, such as CD20, are present only in about 25% of the cases. The aim of the present study was to assess expression of the B-cell-related antigens CD20, CD79a, and CD138 in classical Hodgkin lymphoma using a tissue microarray consisting of 330 classical Hodgkin lymphoma cases. Expression of CD15, CD20, CD30, CD79a, CD138, and latent membrane protein 1 of Epstein-Barr virus was assessed by immunohistochemistry, and the methodology was validated by direct comparison of CD20 expression on the tissue microarray cores with corresponding large sections. The influence of the number of arrayed sample cores on the obtained expression levels of CD20 was analyzed by comparing the results from single, duplicate, and triplicate cores. Two-hundred fifty-three (77%) of the 330 cases were morphologically representative. CD20 was expressed in 84 cases (33%), CD79a in 26 (10%), and CD138 in 2 (1%), respectively. CD20 and CD79a were co-expressed in 16 cases (P <.005), and expression of CD20 correlated inversely with CD15 (P <.01). Comparing the tissue microarray results with those from conventional sections for expression of CD20 yielded a concordance of 94% (63/67). Examining one, two, and three cores from individual cases revealed positivity for CD20 at 24% (61/253), 32% (82/253), and 33% (84/253), respectively. We conclude that B-cell markers are expressed in 38% of classical Hodgkin lymphoma in the following rank order: CD20>CD79a>>CD138. The use of two cores per tissue sample renders the tissue microarray technology effectively representative and thus very useful for high-throughput evaluation of heterogeneously expressed markers in classical Hodgkin lymphoma.
Similar articles
- Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.
Zettl A, Rüdiger T, Marx A, Müller-Hermelink HK, Ott G. Zettl A, et al. Histopathology. 2005 Feb;46(2):217-28. doi: 10.1111/j.1365-2559.2005.02046.x. Histopathology. 2005. PMID: 15693895 - Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
Buettner M, Greiner A, Avramidou A, Jäck HM, Niedobitek G. Buettner M, et al. Hematol Oncol. 2005 Sep-Dec;23(3-4):127-32. doi: 10.1002/hon.764. Hematol Oncol. 2005. PMID: 16342298 Review. - Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.
Huang Q, Wilczynski SP, Chang KL, Weiss LM. Huang Q, et al. Am J Clin Pathol. 2006 Aug;126(2):222-9. doi: 10.1309/DDGL-WRV3-KR91-64G7. Am J Clin Pathol. 2006. PMID: 16891197 - BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
Hoeller S, Zihler D, Zlobec I, Obermann EC, Pileri SA, Dirnhofer S, Tzankov A. Hoeller S, et al. Histopathology. 2010 Jan;56(2):217-28. doi: 10.1111/j.1365-2559.2009.03462.x. Histopathology. 2010. PMID: 20102401 - [Molecular biology aspects of Hodgkin's disease].
Macák J. Macák J. Vnitr Lek. 1998 Jun;44(6):370-2. Vnitr Lek. 1998. PMID: 9820063 Review. Czech.
Cited by
- Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed-Sternberg Cells in 10 High-Power Fields Have Better Prognosis.
Lacet DFR, Oliveira CC. Lacet DFR, et al. Indian J Hematol Blood Transfus. 2022 Jul;38(3):596-600. doi: 10.1007/s12288-021-01517-7. Epub 2022 Jan 9. Indian J Hematol Blood Transfus. 2022. PMID: 35747562 Free PMC article. - Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.
Takahara T, Satou A, Tsuzuki T, Nakamura S. Takahara T, et al. Diagnostics (Basel). 2022 Jun 20;12(6):1507. doi: 10.3390/diagnostics12061507. Diagnostics (Basel). 2022. PMID: 35741318 Free PMC article. Review. - Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.
Barh D, Tiwari S, Gabriel Rodrigues Gomes L, Weener ME, Alzahrani KJ, Alsharif KF, Aljabali AAA, Tambuwala MM, Lundstrom K, Hassan SS, Serrano-Aroca Á, Takayama K, Ghosh P, Redwan EM, Silva Andrade B, Soares SC, Azevedo V, Uversky VN. Barh D, et al. Viruses. 2021 Sep 25;13(10):1927. doi: 10.3390/v13101927. Viruses. 2021. PMID: 34696358 Free PMC article. - Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia.
Adam M, Bekueretsion Y, Abubeker A, Tadesse F, Kwiecinska A, Howe R, Petros B, Jerkeman M, Gebremedhin A. Adam M, et al. JCO Glob Oncol. 2021 Feb;7:277-288. doi: 10.1200/GO.20.00391. JCO Glob Oncol. 2021. PMID: 33591838 Free PMC article. - Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.
Sakatani A, Igawa T, Okatani T, Fujihara M, Asaoku H, Sato Y, Yoshino T. Sakatani A, et al. J Clin Exp Hematop. 2020 Sep 25;60(3):78-86. doi: 10.3960/jslrt.20010. Epub 2020 Jul 8. J Clin Exp Hematop. 2020. PMID: 32641598 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous